https://edgen.dev.edgen.tech/news/post/tesla-stock-drops-21-as-five-year-sp-500-lag-persists2026-08-28T13:07:50.334Zdaily1Edgen Stocken2026-08-28T13:07:50.334+00:00Tesla stock drops 21% as five-year S&P 500 lag persistshttps://static.edwealth.ai/news/images/tesla-stock-drops-21-as-five-year-sp-500-lag-persists-20260828.pngTesla stock drops 21% as five-year S&P 500 lag persists https://edgen.dev.edgen.tech/news/post/novavax-nuvaxovid-secures-3-market-approvals-as-protein-vaccine-gains-ground2026-08-28T13:06:15.922Zdaily1Edgen Stocken2026-08-28T13:06:15.922+00:00Novavax Nuvaxovid secures 3-market approvals as protein vaccine gains groundhttps://static.edwealth.ai/news/images/novavax-nuvaxovid-secures-3-market-approvals-as-protein-vaccine-gains-ground-20260828.pngNovavax Nuvaxovid secures 3-market approvals as protein vaccine gains ground https://edgen.dev.edgen.tech/news/post/biotechs-85-rally-faces-chinas-fast-follower-drug-threat2026-08-28T13:04:33.630Zdaily1Edgen Stocken2026-08-28T13:04:33.630+00:00Biotech's 85% rally faces China's fast-follower drug threathttps://static.edwealth.ai/news/images/biotechs-85-rally-faces-chinas-fast-follower-drug-threat-20260828.pngBiotech's 85% rally faces China's fast-follower drug threat https://edgen.dev.edgen.tech/news/post/japans-record-154-trillion-yen-intervention-fades-as-fundamentals-bite2026-08-28T13:01:51.443Zdaily1Edgen Stocken2026-08-28T13:01:51.443+00:00Japan's Record ¥15.4 Trillion Yen Intervention Fades as Fundamentals Bitehttps://static.edwealth.ai/news/images/japans-record-154-trillion-yen-intervention-fades-as-fundamentals-bite-20260828.pngJapan's Record ¥15.4 Trillion Yen Intervention Fades as Fundamentals Bite https://edgen.dev.edgen.tech/news/post/yen-intervention-fades-japan-equities-hold-as-currency-sits-20-undervalued2026-08-28T13:01:08.057Zdaily1Edgen Stocken2026-08-28T13:01:08.057+00:00Yen Intervention Fades, Japan Equities Hold as Currency Sits 20% Undervaluedhttps://static.edwealth.ai/news/images/yen-intervention-fades-japan-equities-hold-as-currency-sits-20-undervalued-20260828.pngYen Intervention Fades, Japan Equities Hold as Currency Sits 20% Undervalued https://edgen.dev.edgen.tech/news/post/insulet-investors-face-aug-31-lead-plaintiff-deadline-in-class-action2026-08-28T12:58:09.083Zdaily1Edgen Stocken2026-08-28T12:58:09.083+00:00Insulet investors face Aug. 31 lead plaintiff deadline in class actionhttps://static.edwealth.ai/news/images/insulet-investors-face-aug-31-lead-plaintiff-deadline-in-class-action-20260828.pngInsulet investors face Aug. 31 lead plaintiff deadline in class action https://edgen.dev.edgen.tech/news/post/koreas-135-trillion-pension-fund-posts-record-27-return2026-08-28T12:50:42.667Zdaily1Edgen Stocken2026-08-28T12:50:42.667+00:00Korea's $1.35 trillion pension fund posts record 27% returnhttps://static.edwealth.ai/news/images/koreas-135-trillion-pension-fund-posts-record-27-return-20260828.pngKorea's $1.35 trillion pension fund posts record 27% return https://edgen.dev.edgen.tech/news/post/kazia-therapeutics-prices-40-million-offering-to-fund-breast-cancer-trials2026-08-28T12:49:25.868Zdaily1Edgen Stocken2026-08-28T12:49:25.868+00:00Kazia Therapeutics prices $40 million offering to fund breast cancer trialshttps://static.edwealth.ai/news/images/kazia-therapeutics-prices-40-million-offering-to-fund-breast-cancer-trials-20260828.pngKazia Therapeutics prices $40 million offering to fund breast cancer trials https://edgen.dev.edgen.tech/news/post/japans-record-987-billion-yen-rescue-echoes-1997-crisis2026-08-28T12:45:42.458Zdaily1Edgen Stocken2026-08-28T12:45:42.458+00:00Japan's record $98.7 billion yen rescue echoes 1997 crisishttps://static.edwealth.ai/news/images/japans-record-987-billion-yen-rescue-echoes-1997-crisis-20260828.pngJapan's record $98.7 billion yen rescue echoes 1997 crisis https://edgen.dev.edgen.tech/news/post/byd-h1-profit-drops-205-to-rmb123b-on-china-price-war2026-08-28T12:40:42.497Zdaily1Edgen Stocken2026-08-28T12:40:42.497+00:00BYD H1 profit drops 20.5% to RMB12.3B on China price warhttps://static.edwealth.ai/news/images/byd-h1-profit-drops-205-to-rmb123b-on-china-price-war-20260828.pngBYD H1 profit drops 20.5% to RMB12.3B on China price war https://edgen.dev.edgen.tech/news/post/biocryst-eyes-rare-disease-deals-with-645m-orladeyo-engine2026-08-28T12:40:04.146Zdaily1Edgen Stocken2026-08-28T12:40:04.146+00:00BioCryst eyes rare disease deals with $645M Orladeyo enginehttps://static.edwealth.ai/news/images/biocryst-eyes-rare-disease-deals-with-645m-orladeyo-engine-20260828.pngBioCryst eyes rare disease deals with $645M Orladeyo engine https://edgen.dev.edgen.tech/news/post/fda-approves-lillys-mounjaro-to-cut-cardiovascular-risk-82026-08-28T12:35:27.522Zdaily1Edgen Stocken2026-08-28T12:35:27.522+00:00FDA approves Lilly's Mounjaro to cut cardiovascular risk 8%https://static.edwealth.ai/news/images/fda-approves-lillys-mounjaro-to-cut-cardiovascular-risk-8-20260828.pngFDA approves Lilly's Mounjaro to cut cardiovascular risk 8% https://edgen.dev.edgen.tech/news/post/silver-up-18-in-august-as-xagusd-hits-two-month-high2026-08-28T12:32:45.266Zdaily1Edgen Stocken2026-08-28T12:32:45.266+00:00Silver up 18% in August as XAG/USD hits two-month highhttps://static.edwealth.ai/news/images/silver-up-18-in-august-as-xagusd-hits-two-month-high-20260828.pngSilver up 18% in August as XAG/USD hits two-month high https://edgen.dev.edgen.tech/news/post/moderna-prices-26-billion-convertible-notes-to-fund-oncology-push2026-08-28T12:25:28.316Zdaily1Edgen Stocken2026-08-28T12:25:28.316+00:00Moderna prices $2.6 billion convertible notes to fund oncology pushhttps://static.edwealth.ai/news/images/moderna-prices-26-billion-convertible-notes-to-fund-oncology-push-20260828.pngModerna prices $2.6 billion convertible notes to fund oncology push https://edgen.dev.edgen.tech/news/post/china-extends-home-loan-terms-to-40-years-in-credit-overhaul2026-08-28T12:24:59.254Zdaily1Edgen Stocken2026-08-28T12:24:59.254+00:00China Extends Home Loan Terms to 40 Years in Credit Overhaulhttps://static.edwealth.ai/news/images/china-extends-home-loan-terms-to-40-years-in-credit-overhaul-20260828.pngChina Extends Home Loan Terms to 40 Years in Credit Overhaul https://edgen.dev.edgen.tech/news/post/country-garden-narrows-1h26-loss-to-rmb156b-as-revenue-slides-392026-08-28T12:20:41.318Zdaily1Edgen Stocken2026-08-28T12:20:41.318+00:00Country Garden narrows 1H26 loss to RMB15.6B as revenue slides 39%https://static.edwealth.ai/news/images/country-garden-narrows-1h26-loss-to-rmb156b-as-revenue-slides-39-20260828.pngCountry Garden narrows 1H26 loss to RMB15.6B as revenue slides 39% https://edgen.dev.edgen.tech/news/post/didi-commits-200-million-to-argentina-as-latin-america-expansion-accelerates2026-08-28T12:18:34.277Zdaily1Edgen Stocken2026-08-28T12:18:34.277+00:00Didi commits $200 million to Argentina as Latin America expansion accelerateshttps://static.edwealth.ai/news/images/didi-commits-200-million-to-argentina-as-latin-america-expansion-accelerates-20260828.pngDidi commits $200 million to Argentina as Latin America expansion accelerates https://edgen.dev.edgen.tech/news/post/lucid-recalls-27185-air-sedans-over-exterior-lighting-fire-risk2026-08-28T12:01:35.005Zdaily1Edgen Stocken2026-08-28T12:01:35.005+00:00Lucid recalls 27,185 Air sedans over exterior lighting fire riskhttps://static.edwealth.ai/news/images/lucid-recalls-27185-air-sedans-over-exterior-lighting-fire-risk-20260828.pngLucid recalls 27,185 Air sedans over exterior lighting fire risk https://edgen.dev.edgen.tech/news/post/changxin-technology-posts-874-revenue-surge-as-ai-memory-demand-soars2026-08-28T11:58:32.093Zdaily1Edgen Stocken2026-08-28T11:58:32.093+00:00ChangXin Technology posts 874% revenue surge as AI memory demand soarshttps://static.edwealth.ai/news/images/changxin-technology-posts-874-revenue-surge-as-ai-memory-demand-soars-20260828.pngChangXin Technology posts 874% revenue surge as AI memory demand soars https://edgen.dev.edgen.tech/news/post/cytokinetics-aficamten-clears-both-endpoints-in-517-patient-heart-trial2026-08-28T11:55:53.104Zdaily1Edgen Stocken2026-08-28T11:55:53.104+00:00Cytokinetics aficamten clears both endpoints in 517-patient heart trialhttps://static.edwealth.ai/news/images/cytokinetics-aficamten-clears-both-endpoints-in-517-patient-heart-trial-20260828.pngCytokinetics aficamten clears both endpoints in 517-patient heart trial